Ironwood Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Ironwood Pharmaceuticals has a total shareholder equity of $-321.7M and total debt of $623.6M, which brings its debt-to-equity ratio to -193.8%. Its total assets and total liabilities are $395.6M and $717.3M respectively. Ironwood Pharmaceuticals's EBIT is $119.3M making its interest coverage ratio 4.3. It has cash and short-term investments of $105.5M.
Key information
-193.8%
Debt to equity ratio
US$623.65m
Debt
| Interest coverage ratio | 4.3x |
| Cash | US$105.52m |
| Equity | -US$321.73m |
| Total liabilities | US$717.35m |
| Total assets | US$395.62m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: I76 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: I76's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: I76's debt is well covered by operating cash flow (23.5%).
Interest Coverage: I76's interest payments on its debt are well covered by EBIT (4.3x coverage).